CROI 2016 Program at a Glance

Program and Agenda

Session P-X8 Poster Abstracts

Hall D

1030 Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa Dami A. Collier 1 ; Kathy Baisley 2 ; Dickman Gareta 3 ; Deenan Pillay 3 ; Ravindra K. Gupta 1 1 UnivCollLondon,London,UK; 2 LondonSchofHygiene&TropMed, London,UK; 3 AfricaCntr forHlthandPopStudies,Mtubatuba,South Africa 1031 Outcomes of Patients Enrolled in ART Adherence Clubs After Viral Resuppression JosephT. Sharp 1 ; LynneWilkinson 2 ;Vivian Cox 2 ; Carol Cragg 3 ; Gilles Van Cutsem 4 ; Anna Grimsrud 5 1 UnivofCapeTown,CapeTown,SouthAfrica; 2 MédecinsSansFrontières, Khayelitsha,SouthAfrica; 3 WesternCapeDeptofHlth,CapeTown,South Africa; 4 MédecinsSansFrontières,CapeTown,SouthAfrica; 5 IAS,Cape Town,SouthAfrica 1032 Substance Use Is a Major Barrier to Viral Suppression Among Key Populations in India Sunil S. Solomon 1 ; Gregory M. Lucas 1 ; Aylur K. Srikrishnan 2 ; Allison M. McFall 1 ; David Celentano 1 ; Shanmugam Saravanan 3 ; Suresh Kumar 2 ; Shruti H. Mehta 1 1 JohnsHopkinsUniv,Baltimore,MD,USA; 2 YRGCntr forAIDSRsrand Educ,Taramani, India; 3 YRGCntr forAIDSRsrandEduc,Chennai, India 1033 Durable Viral Suppression Among HIV-Diagnosed Persons United States, 2012–2013 Nicole Crepaz 1 ;TianTang 2 ; Gary Marks 1 ; Michael J. Mugavero 3 ; Lorena Espinoza 1 ; H. Irene Hall 1 1 CDC,Atlanta,GA,USA; 2 ICF Intl,Atlanta,GA,USA; 3 UnivofAlabamaat Birmingham,Birmingham,AL,USA 1034 Changes in Viral Load Across US Clinics Over Time Jane Simoni 1 ; Robin Nance 1 ; Joseph A. Delaney 2 ; Ira B.Wilson 3 ; Frances Aunon 1 ; Steven A. Safren 4 ; Michael J. Mugavero 5 ; Kenneth H. Mayer 6 ; Mari M. Kitahata 1 ; Heidi M. Crane 1 1 UnivofWashington,Seattle,WA,USA; 2 UnivofWashingtonSchof PHandCommunityMed,Seattle,WA,USA; 3 BrownUnivSchofPH, Providence,RI,USA; 4 MassachusettsGeneralHosp,Boston,MA,USA; 5 UnivofAlabamaatBirmingham,Birmingham,AL,USA; 6 TheFenway Inst,FenwayHlth,Boston,MA,USA 1035 Differences in HIV Viral Suppression by Frequency and Type of Healthcare Visits Michael A. Horberg 1 ; Jackie Blank 1 ; Kevin B. Rubenstein 1 ; Leo B. Hurley 2 ; Julia L. Marcus 2 ; Daniel B. Klein 3 ; Peter M. Kadlecik 4 ; Michael J. Silverberg 2 1 Mid-AtlanticPermanenteMedGroup,Rockville,MD,USA; 2 Kaiser PermanenteNorthernCalifornia,Oakland,CA,USA; 3 KaiserPermanente SanLeandroMedCntr,SanLeandro,CA,USA; 4 Mid-AtlanticPermanente MedGroup,Washington,DC,USA 1036 Community Viral Load: Measure Validation and Public Health Utility Kathryn M. Leifheit 1 ; Christina Schumacher 1 ; Patrick Chaulk 2 ; Carolyn Nganga-Good 2 ; Jacky M. Jennings 1 1 JohnsHopkinsUnivSchofMed,Baltimore,MD,USA; 2 BaltimoreCityHlth Dept,Baltimore,MD,USA

2:45 PM-4:00 PM Viral Suppression 1024 Feasibility of the Third 90-90-90 Target: Viral Load Coverage and Outcomes in Rwanda Muhayimpundu Ribakare 1 ; Jean d’Amour Ndahimana 1 ; Byiringiro Rusisiro 1 ; Gad Niyibizi 1 ; Jean Paul Uwizihiwe 2 ; Catherine Kirk 3 ; Sabin Nsanzimana 1 1 RwandaBiomedCntr,Kigali,Rwanda; 2 InstofHIV/AIDSDisease PreventionandControl,RwandaBiomedCntr,Kigali,Rwanda; 3 Partners InHlth,Kigali,Rwanda 1025 ART Coverage and Viral Load in Tanzania: Bukoba Combination Prevention Baseline Study Sarah E. Porter 1 ; Duncan MacKellar 1 ; RachelWeber 2 ; Haruka Maruyama 3 ; Sherri Pals 1 ; Gretchen Antelman 4 ; Oscar Ernest 5 ; Robert Josiah 6 ; Jessica Justman 7 1 CDC,Atlanta,GA,USA; 2 CTSGlobal, Inc,Assigned toUSCDC,Dares Salaam,Tanzania; 3 ICAPatColumbiaUniv,DaresSalaam,Tanzania; 4 ElizabethGlaserPediatricAIDSFndn,DaresSalaam,Tanzania; 5 ICAP atColumbiaUniv,Bukoba,Tanzania; 6 NatlAIDSControlProg,Dares Salaam,Tanzania; 7 ICAPatColumbiaUniv,NewYork,NY,USA 1026 Heterogeneity in Local Population Viremia Despite >50% Suppression in East Africa Vivek Jain 1 ; Dathan Byonanebye 2 ;Teri Liegler 1 ; Dalsone Kwarisiima 3 ; Norton Sang 4 ; Edwin Charlebois 1 ; Maya Petersen 5 ; Moses R. Kamya; DianeV. Havlir 1 ; for the SEARCH Collaboration 1 UnivofCaliforniaSanFrancisco,SanFrancisco,CA,USA; 2 MakerereUniv CollofHlthScis,Kampala,Uganda; 3 MakerereUniv-UnivofCalifornia SanFranciscoRsrCollab,Kampala,Uganda; 4 KenyaMedRsr Inst,Nairobi, Kenya; 5 UnivofCaliforniaBerkeley,Berkeley,CA,USA 1027 High Rate of Viral Suppression in Late Mortality on First-Line ART in Uganda/Zimbabwe 1 MedRsrCouncilClinicalTrialsUnitatUnivCollLondon,London,UK; 2 MedRsrCouncil/UgandaVirusRsr InstUgandaRsrUnitonAIDS, Entebbe,Uganda; 3 SchofPopHlth,UnivofQueensland,Herston, Australia; 4 AfricaCntr forHlthandPopStudies,Mtubatuba,SouthAfrica 1028 Measuring Viral Load Suppression in South Africa Using a Novel, National Database William B. MacLeod 1 ; Jacob Bor 1 ; Nicole Fraser 2 ; Zara Shubber 2 ; Ian M. Sanne 3 ;Wendy Stevens 4 ;Tshepo Molapo 5 ; Mokgadi Phokojoe 5 ; Yogan Pillay 5 ; Sergio Carmona 6 1 BostonUnivSchofPH,Boston,MA,USA; 2 TheWorldBank,Washington, DC,USA; 3 Univof theWitwatersrand,WitsHlthConsortium, Johannesburg,SouthAfrica; 4 Univof theWitwatersrand, Johannesburg, SouthAfrica; 5 NatlDeptofHlth,Pretoria,SouthAfrica; 6 NatlHlthLab Service/WitsUniv, Johannesburg,SouthAfrica 1029 Comparing Adherence Methods: Which Best Predicts Virological and Resistance Outcome? Catherine Orrell 1 ; Karen Cohen 1 ; Rory Leisegang 1 ; David R. Bangsberg 2 ; Gary Maartens 1 ; RobinWood 1 1 UnivofCapeTown,CapeTown,SouthAfrica; 2 HarvardMedSch,Boston, MA,USA David I. Dolling 1 ; Pontiano Kaleebu 2 ; Peter Nkurunziza 2 ; Moira Spyer 1 ; Charles Gilks 3 ; Deenan Pillay 4 ; Ruth Goodall 1 ; for the DART Virology Group

Poster Listings

CROI 2016 126